Nasdaq · Technology
Cellebrite DI Ltd. (CLBT)
As-reported financials and recent SEC filings for Cellebrite DI Ltd., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$475.7M
Net income
$78.3M
Net margin
16.5%
Diluted EPS
$0.31
ROE
16.2%
P/E (TTM)
49.1×
Market cap
$3.43B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2022 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $475.7M | $401.2M | $325.1M | $270.7M | $246.2M |
| Gross profit | $400.5M | $338.6M | $271.9M | $219.9M | $203.7M |
| Operating income | $66.5M | $56.9M | $33.2M | $1.0M | $13.8M |
| Net income | $78.3M | $-283.0M | $-81.1M | $120.8M | $71.4M |
| Diluted EPS | $0.31 | $-1.35 | $-0.43 | $0.59 | $0.44 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-01
View on EDGAR →42026-05-26
View on EDGAR →1442026-05-21
View on EDGAR →1442026-05-21
View on EDGAR →42026-05-19
View on EDGAR →1442026-05-18
View on EDGAR →42026-05-14
View on EDGAR →42026-05-14
View on EDGAR →Go deeper on CLBT
Search Cellebrite DI Ltd.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.